



APRIL 2021

GLOBAL ASSET ALLOCATION VIEWPOINTS AND INVESTMENT ENVIRONMENT

1 MARKET PERSPECTIVE As of 31 March 2021

- Global economic growth expected to accelerate particularly in the back half of the year as reopenings unleash pent-up demand, while still supported by accommodative monetary policies and additional fiscal spending particularly in the U.S.
- Global inflation expectations likely to trend higher as growth accelerates, supported by stronger commodities and central bankers allowing higher inflation in favor of sustained labor market recovery.
- Asian and European economies may benefit more amid the recovery given higher cyclical exposure relative to the U.S., although aggressive fiscal spending in the U.S. could provide a tailwind.
- Key risks to global markets include the pace of vaccinations, coronavirus mutations, potential for higher taxes as countries pivot to funding recovery costs and geopolitical concerns.

2 PORTFOLIO POSITIONING As of 31 March 2021

- We shifted to a modest underweight to equities relative to bonds and cash as the risk/reward profile of equities looks less attractive after a strong multiple-driven rebound since last March's lows.
- Within fixed income, we favor less interest rate- and more inflation-sensitive sectors when possible. We use cash and unconstrained bond strategies to diversify the portfolio.
- Within equities, we are further tilting into value based on more attractive relative valuations and continued improvement in economic data, bolstered by fiscal stimulus in the U.S. and higher interest rates.
- We moderated our overweight to small-cap stocks following a 100%+ return since the lows of last March; while smaller companies may continue to benefit from aggressive fiscal and consumer spending, valuations in some sectors are getting rich.

3 MARKET THEMES As of 31 March 2021

Closing the Gap


As investors grew more optimistic late last year about the global economic recovery, small-cap stocks took off with a parabolic snapback, up over 100% since the lows of last March. While smaller companies tend to lead early in an economic recovery given their higher sensitivity to growth, the fast and furious pace of performance stands out. Meanwhile, cyclically oriented value stocks, which are also highly reliant on the trajectory of economic growth, have just begun to make up ground from the sell-off. While smaller companies may continue to benefit from reopening and stimulus in the U.S., a lot of the outperformance may be behind small-caps, while value stocks are likely to continue to benefit from the recovery, stimulus, higher rates, and the potential for infrastructure spending. After nearly a decade of underperformance, perhaps this cyclical rally may be enough for value to close the gap versus growth stocks.

Reason to Worry?

Equity markets are riding higher on unwavering optimism, which have driven the S&P 500 up over 20% above its pre-COVID-19 levels. Despite higher valuations, bouts of risk, and pockets of froth in the market—such as in bitcoin, home prices, and special purpose acquisition companies—investors appear to have little concern. Perhaps there is no alternative to investing in equities with bond yields on the rise, but it's hard to ignore events such as the retail investor GameStop short squeeze and enormous losses at Archegos Capital, a large private family office, which may have historically shaken the confidence of equity investors. While recent bad news is largely viewed as idiosyncratic, market valuations continue to get more extended, and the risk of one of these events sparking a more systemic sell-off could increase. But perhaps the systemic risk is already here, with the threat of even higher rates, inflation, and now taxes.

Small-cap & Value Relative Performance¹

(Fig. 1) From 23 March 2020 to 31 March 2021



S&P 500 & U.S. 10-Year Treasury Yield

(Fig. 2) From 18 February 2020 to 31 March 2021



Past performance is not a reliable indicator of future performance.


¹ Small-cap represented by Russell 2000 Index. Large-cap represented by Russell 1000 Index. Value represented by Russell 1000 Value Index. Growth represented by Russell 1000 Growth Index. Sources: Standard & Poor's, Bloomberg Finance L.P., Russell, London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). T. Rowe Price calculations using data from FactSet Research Systems Inc. All rights reserved. See additional disclosures on final page for more information.

For Investment Professionals only. Not for further distribution.

4 REGIONAL BACKDROP

As of 31 March 2021

	Positives	Negatives
United States	<ul style="list-style-type: none">■ More fiscal support on the way■ Pace of vaccinations has been strong■ Monetary policy remains very accommodative■ Healthy consumer balance sheets and high savings rate	<ul style="list-style-type: none">■ Elevated stock and bond valuations■ Corporate and government debt at high levels■ Corporate taxes likely to rise■ Unemployment remains elevated
Europe	<ul style="list-style-type: none">■ Higher exposure to more cyclically oriented sectors that should benefit from economic recovery■ Monetary and fiscal policy remain accommodative■ Equity valuations remain attractive to the U.S.■ Stronger long-term euro outlook	<ul style="list-style-type: none">■ Lockdowns back on due to third wave of COVID-19■ Vaccination effort facing supply shortages■ Limited long-term catalysts for growth■ Limited scope for European Central Bank to stimulate further■ Brexit likely to negatively impact trade
China	<ul style="list-style-type: none">■ Economic growth remains solid, supported by strong exports and a rebound in domestic consumption. Earnings rebound should likely follow through.■ Policy targets (i.e., growth and fiscal deficit) allow for some flexibility in the path to normalization■ Demand for Chinese assets should likely attract inflows this year, adding pressure to bond yields and supporting the RMB	<ul style="list-style-type: none">■ Early signs of inflationary pressures and supply bottlenecks are concerning■ Policymakers made clear statements that they want to avoid asset bubbles in the stock market and property sector■ Valuations and sentiment indicators are headwinds to the equity markets
Japan	<ul style="list-style-type: none">■ Leading economic indicators are finally breaking through the expansion levels. The recovery should likely accelerate in upcoming months.■ Domestic stocks are a global reflation play, with positive correlations to PMIs and bond yields■ Earnings revision ratios are close to record levels. A weaker JPY doesn't hurt.	<ul style="list-style-type: none">■ Price momentum in equity markets is calling for a pause in the appreciation trend in the near term■ COVID-19 vaccines are being administered late relative to other countries, while the pandemic is still not yet under control■ Bank of Japan dropped the annual ETF buying target, causing some concerns regarding its faculty to remain the buyer of last resort
Australia	<ul style="list-style-type: none">■ The economy is roaring, evidenced by a broad range of indicators on business activity, consumer spending and employment■ Earnings are following through, benefitting from high commodity prices and record low yields■ The central bank was extremely dovish, indicating any policy normalization may be a long way off	<ul style="list-style-type: none">■ Early signs of inflationary pressures seen in the housing and construction markets■ Yields have risen, challenging the central bank's policies. The valuation gap between stocks and bonds is not as attractive anymore.■ Although the AUD's recent weakening trend supports an earnings recovery, it is also at odds with strength in the economy. Is it an early sign of the domestic recovery peaking?
Emerging Markets	<ul style="list-style-type: none">■ Exposure to cyclical areas of economy should benefit from broad global recovery■ Commodity prices rising■ Chinese economy remains strong■ Equity valuations attractive relative to developed markets	<ul style="list-style-type: none">■ Stimulus from China likely to fade going forward■ Limited ability to enact fiscal stimulus (excluding China)■ Vaccine supply and distribution infrastructure are well behind developed markets■ Inflationary pressures are rising in some countries



¹For pairwise decisions in style & market capitalization, positioning within boxes represent positioning in the first mentioned asset class relative to the second asset class.



REGIONAL MULTI-ASSET TEAM REPRESENTATIVES



Thomas Poullaouec
Head of Multi-Asset
Solutions APAC



Wenting Shen
Multi-Asset Solutions
Strategist



Hajime Takigawa
Multi-Asset Solutions
Strategist

ADDITIONAL DISCLOSURES

Certain numbers in this report may not equal stated totals due to rounding.

Source: Unless otherwise stated, all market data are sourced from FactSet. Financial data and analytics provider FactSet. Copyright 2021 FactSet. All Rights Reserved.

Bloomberg Index Services Limited. BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively "Bloomberg"). BARCLAYS® is a trademark and service mark of Barclays Bank Plc (collectively with its affiliates, "Barclays"), used under license. Bloomberg or Bloomberg's licensors, including Barclays, own all proprietary rights in the Bloomberg Barclays Indices. Neither Bloomberg nor Barclays approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.

The "S&P 500 Index" is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates ("SPDJ") and has been licensed for use by T. Rowe Price. Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC, a division of S&P Global ("S&P"); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"). This product is not sponsored, endorsed, sold or promoted by SPDJ, Dow Jones, S&P or their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P 500 Index.

London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2021. FTSE Russell is a trading name of certain of the LSE Group companies. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. Bloomberg Finance L.P.

Important Information

The specific securities identified and described are for informational purposes only and do not represent recommendations.

This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. **Past performance is not a reliable indicator of future performance.** The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.

It is not intended for distribution to retail investors in any jurisdiction.

Australia—Issued in Australia by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. For Wholesale Clients only.

Brunei—This material can only be delivered to certain specific institutional investors for informational purpose upon request only. The strategy and/or any products associated with the strategy has not been authorised for distribution in Brunei. No distribution of this material to any member of the public in Brunei is permitted.

China—This material is provided to specific qualified domestic institutional investor or sovereign wealth fund on a one-on-one basis. No invitation to offer, or offer for, or sale of, the shares will be made in the People's Republic of China ("PRC") (which, for such purpose, does not include the Hong Kong or Macau Special Administrative Regions or Taiwan) or by any means that would be deemed public under the laws of the PRC. The information relating to the strategy contained in this material has not been submitted to or approved by the China Securities Regulatory Commission or any other relevant governmental authority in the PRC. The strategy and/or any product associated with the strategy may only be offered or sold to investors in the PRC that are expressly authorized under the laws and regulations of the PRC to buy and sell securities denominated in a currency other than the Renminbi (or RMB), which is

the official currency of the PRC. Potential investors who are resident in the PRC are responsible for obtaining the required approvals from all relevant government authorities in the PRC, including, but not limited to, the State Administration of Foreign Exchange, before purchasing the shares. This document further does not constitute any securities or investment advice to citizens of the PRC, or nationals with permanent residence in the PRC, or to any corporation, partnership, or other entity incorporated or established in the PRC.

Hong Kong—Issued in Hong Kong by T. Rowe Price Hong Kong Limited, 6/F Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. For Professional Investors only.

Indonesia—This material is intended to be used only by the designated recipient to whom T. Rowe Price delivered; it is for institutional use only. Under no circumstances should the material, in whole or in part, be copied, redistributed or shared, in any medium, without prior written consent from T. Rowe Price. No distribution of this material to members of the public in any jurisdiction is permitted.

Korea—This material is intended only to Qualified Professional Investors upon specific and unsolicited request and may not be reproduced in whole or in part nor can they be transmitted to any other person in the Republic of Korea.

Malaysia—This material can only be delivered to specific institutional investor upon specific and unsolicited request. The strategy and/or any products associated with the strategy has not been authorised for distribution in Malaysia. This material is solely for institutional use and for informational purposes only. This material does not provide investment advice or an offering to make, or an inducement or attempted inducement of any person to enter into or to offer to enter into, an agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. Nothing in this material shall be considered a making available of, solicitation to buy, an offering for subscription or purchase or an invitation to subscribe for or purchase any securities, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of Malaysia.

New Zealand—Issued in New Zealand by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.

Philippines—THE STRATEGY AND/ OR ANY SECURITIES ASSOCIATED WITH THE STRATEGY BEING OFFERED OR SOLD HEREIN HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE. ANY FUTURE OFFER OR SALE OF THE STRATEGY AND/ OR ANY SECURITIES IS SUBJECT TO REGISTRATION REQUIREMENTS UNDER THE CODE, UNLESS SUCH OFFER OR SALE QUALIFIES AS AN EXEMPT TRANSACTION.

Singapore—Issued in Singapore by T. Rowe Price Singapore Private Ltd., No. 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and regulated by the Monetary Authority of Singapore. For Institutional and Accredited Investors only.

Taiwan—This does not provide investment advice or recommendations. Nothing in this material shall be considered a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person in the Republic of China.

Thailand—This material has not been and will not be filed with or approved by the Securities Exchange Commission of Thailand or any other regulatory authority in Thailand. The material is provided solely to "institutional investors" as defined under relevant Thai laws and regulations. No distribution of this material to any member of the public in Thailand is permitted. Nothing in this material shall be considered a provision of service, or a solicitation to buy, or an offer to sell, a security, or any other product or service, to any person where such provision, offer, solicitation, purchase or sale would be unlawful under relevant Thai laws and regulations.

© 2021 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE and the bighorn sheep design are, collectively and/or apart, trademarks or registered trademarks of T. Rowe Price Group, Inc.

202104-1599157
APAC-PAN-2040
ID0004198